OKYO Pharma Limited (OKYO) Wednesday announced promising categorical data from the Phase 2 study of its OK-101 ophthalmic solution in patients with dry eye disease.
Results from the Phase 2 study were analyzed by categorical evaluation of the data set and responder-rate analyses.
The analyses showed that 34.2 percent of patients treated with OK-101 showed both a reduction in conjunctival sum staining and in the pain symptom compared with 20.3 percent on placebo. Similarly, the number of patients with reduction in conjunctival sum staining and burning/stinging symptoms were also higher at 32.9 percent in the OK-101-treated group compared to the 20.3 percent placebo-treated group.
"These analyses have identified conjunctival staining and ocular pain as the highest potential "sign" and "symptom" co-primary endpoints to be explored in the next DED trial of OK-101," OKYO Pharma said in a release.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.